IMED strengthens management with new CEO and chairman

LinkMed’s portfolio company IMED is strengthening its management team with a new CEO, Lotta Lungqvist and a new chairman, Carl-Gustaf Johansson. This reinforcement is being made to speed up the pace of development of the company’s work in the area of monoclonal antibodies.

Lotta Ljungqvist has extensive experience in the development of protein-based drugs and joins IMED from Biovitrum, where she was Vice President, Biopharmaceutical Process Development. She is IMED’s first full-time CEO.

Carl-Gustaf Johansson was previously President and CEO of AstraZeneca-US and Executive Vice President of AstraZeneca plc globally. He has also held the positions of President and CEO of Astra Pharmaceuticals US and Executive Vice President of Astra AB.

IMED’s current CEO, Ingemar Lagerlöf, who is also CEO of LinkMed, will now become a member of the Board of Directors of IMED.

In 2007, IMED will speed up the pace of development of monoclonal antibodies that block natural cell death, by performing Investigational New Drug testing (IND) required prior to testing on humans, among other things. The company aims to complete IND testing of its monoclonal antibodies in 2008.

”IMED’s monoclonal antibodies show very interesting properties. By strengthening IMED’s management we are well equipped to reach our goal of quickly and safely preparing for clinical trials,” says Ingemar Lagerlöf.

LinkMed’s ownership stake in IMED is 39 percent.


For further information contact:
Ingemar Lagerlöf, CEO LinkMed.
Tel: +46 (8) 508 939 93